These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 9160680)

  • 21. Modulation of daunorubicin cellular resistance by combination of P-glycoprotein blockers acting on drug efflux and intracellular drug sequestration in Golgi vesicles.
    Merlin JL; Bour-Dill C; Marchal S; Ramacci C; Poullain MG; Giroux B
    Cytometry; 2000 Sep; 41(1):62-72. PubMed ID: 10942898
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Actin disruption inhibits endosomal traffic of P-glycoprotein-EGFP and resistance to daunorubicin accumulation.
    Fu D; Roufogalis BD
    Am J Physiol Cell Physiol; 2007 Apr; 292(4):C1543-52. PubMed ID: 17122416
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833.
    Beketic-Oreskovic L; Durán GE; Chen KG; Dumontet C; Sikic BI
    J Natl Cancer Inst; 1995 Nov; 87(21):1593-602. PubMed ID: 7563202
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance.
    Ross DD; Doyle LA; Yang W; Tong Y; Cornblatt B
    Biochem Pharmacol; 1995 Nov; 50(10):1673-83. PubMed ID: 7503771
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of the P-glycoprotein- and multidrug resistance protein-mediated efflux of anthracyclines and calceinacetoxymethyl ester by PAK-104P.
    Marbeuf-Gueye C; Salerno M; Quidu P; Garnier-Suillerot A
    Eur J Pharmacol; 2000 Mar; 391(3):207-16. PubMed ID: 10729360
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The P-glycoprotein-mediated relative decrease in cytosolic free drug concentration is similar for several anthracyclines with varying lipophilicity.
    Mülder HS; Dekker H; Pinedo HM; Lankelma J
    Biochem Pharmacol; 1995 Sep; 50(7):967-74. PubMed ID: 7575681
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A new anthracycline with potent anti-leukemic activity overcomes P-glycoprotein multidrug resistance.
    Andrivon W; Monneret C; Nafziger J; Florent JC; Guillosson JJ
    Leuk Res; 1998 Aug; 22(8):719-25. PubMed ID: 9680099
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Retention of activity by selected anthracyclines in a multidrug resistant human large cell lung carcinoma line without P-glycoprotein hyperexpression.
    Coley HM; Workman P; Twentyman PR
    Br J Cancer; 1991 Mar; 63(3):351-7. PubMed ID: 1672252
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monensin and verapamil do not alter intracellular localisation of daunorubicin in multidrug resistant human KB cells.
    Wood DJ; Rumsby MG; Warr JR
    Cancer Lett; 1996 Nov; 108(1):41-7. PubMed ID: 8950207
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regulation of cellular glutathione modulates nuclear accumulation of daunorubicin in human MCF7 cells overexpressing multidrug resistance associated protein.
    Benderra Z; Trussardi A; Morjani H; Villa AM; Doglia SM; Manfait M
    Eur J Cancer; 2000 Feb; 36(3):428-34. PubMed ID: 10708946
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The efflux of anthracyclines in multidrug-resistant cell lines.
    Coley HM; Twentyman PR; Workman P
    Biochem Pharmacol; 1993 Oct; 46(8):1317-26. PubMed ID: 7902089
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Daunorubicin and vincristine binding to plasma membrane vesicles from daunorubicin-resistant and wild type Ehrlich ascites tumor cells.
    Sehested M; Bindslev N; Demant EJ; Skovsgaard T; Jensen PB
    Biochem Pharmacol; 1989 Sep; 38(18):3017-27. PubMed ID: 2571333
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human hepatoma cells rich in P-glycoprotein are sensitive to aclarubicin and resistant to three other anthracyclines.
    Lehne G; De Angelis P; Clausen OP; Rugstad HE
    Br J Cancer; 1996 Dec; 74(11):1719-29. PubMed ID: 8956784
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nucleotide-induced conformational changes in the human multidrug resistance protein MRP1 are related to the capacity of chemotherapeutic drugs to accumulate or not in resistant cells.
    Manciu L; Chang X; Riordan JR; Buyse F; Ruysschaert JM
    FEBS Lett; 2001 Mar; 493(1):31-5. PubMed ID: 11278000
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A model for computer simulation of P-glycoprotein and transmembrane delta pH-mediated anthracycline transport in multidrug-resistant tumor cells.
    Demant EJ; Sehested M; Jensen PB
    Biochim Biophys Acta; 1990 Nov; 1055(2):117-25. PubMed ID: 2242381
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative evaluation of the intracellular accumulation and DNA binding of idarubicin and daunorubicin in sensitive and multidrug-resistant human leukaemia K562 cells.
    Bogush T; Robert J
    Anticancer Res; 1996; 16(1):365-8. PubMed ID: 8615637
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selective photodynamic inactivation of a multidrug transporter by a cationic photosensitising agent.
    Kessel D; Woodburn K
    Br J Cancer; 1995 Feb; 71(2):306-10. PubMed ID: 7841045
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anthracycline subcellular distribution in human leukemic cells by microspectrofluorometry: factors contributing to drug-induced cell death and reversal of multidrug resistance.
    Morjani H; Millot JM; Belhoussine R; Sebille S; Manfait M
    Leukemia; 1997 Jul; 11(7):1170-9. PubMed ID: 9205008
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Examination by laser scanning confocal fluorescence imaging microscopy of the subcellular localisation of anthracyclines in parent and multidrug resistant cell lines.
    Coley HM; Amos WB; Twentyman PR; Workman P
    Br J Cancer; 1993 Jun; 67(6):1316-23. PubMed ID: 8099807
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intracellular distribution and pharmacokinetics of daunorubicin in anthracycline-sensitive and -resistant HL-60 cells.
    Hindenburg AA; Gervasoni JE; Krishna S; Stewart VJ; Rosado M; Lutzky J; Bhalla K; Baker MA; Taub RN
    Cancer Res; 1989 Aug; 49(16):4607-14. PubMed ID: 2545346
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.